Vaccines
A new study published in Nature offers good news for those who recovered from COVID-19 and were then vaccinated with a mRNA vaccine – a booster may not be needed.
The groundbreaking success of the mRNA vaccines for COVID-19 by Pfizer-BioNTech and Moderna has led the way for other companies with a vested interest in vaccine development.
The analysis showed that the Pfizer and Oxford/AstraZeneca vaccines can protect patients from being hospitalized by as much as 90 percent.
Concerns over vaccination links to heart inflammation are valid, a U.S. Centers for Disease Control and Prevention advisory committee announced this afternoon.
The two companies will assess the safety and immunogenicity of the vaccine candidate, which codes for the hemagglutinin protein in the A/H3N2 strain of the seasonal flu virus.
Cuba’s Abdala vaccine is 92% effective against the novel coronavirus, according to a recent analysis of late-stage trials.
Please check out the biopharma industry’s COVID-19 stories that are trending for June 22, 2021.
Though the world is reopening, this pandemic is not over. Moderna continues expanding production to answer the call globally.
The new findings likely throw a wrench in the company’s plans to deliver millions of much-needed vaccine doses to the European Union soon.
A recent study conducted by Public Health England found that the available vaccines were “highly effective” at preventing hospitalization after two doses.
PRESS RELEASES